Preview

Regulatory Research and Medicine Evaluation

Advanced search

Preclinical Studies in the Pharmaceutical Development Cycle

https://doi.org/10.30895/1991-2919-2024-14-3-248-250

Abstract

The ultimate goal of preclinical studies is to generate data that can be used to make conclusions about the potential effects of a new medicine on the human body and to properly proceed to clinical trials. In this interview, Marina N. Makarova, Doctor of Medical Sciences, Director of the RMC “HOME OF PHARMACY”, shares her views on conducting preclinical studies in Russia.

About the Author

M. N. Makarova
Research-and-manufacturing company “HOME OF PHARMACY”
Russian Federation

Marina N. Makarova, Dr. Sci. (Med.)

3/245 Zavodskaya St., Kuzmolovsky urban-type settlement, Vsevolozhsky district, Leningrad region 188663



Supplementary files

Review

For citations:


Makarova M.N. Preclinical Studies in the Pharmaceutical Development Cycle. Regulatory Research and Medicine Evaluation. 2024;14(3):248-250. (In Russ.) https://doi.org/10.30895/1991-2919-2024-14-3-248-250

Views: 640


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 3034-3062 (Print)
ISSN 3034-3453 (Online)